About KSQ Therapeutics

KSQ Therapeutics utilizes its CRISPRomics® platform to identify and target the genome's most promising therapeutic candidates for curing human diseases. The company is advancing CRISPR/Cas9-engineered Tumor Infiltrating Lymphocytes (eTIL®) programs to develop effective treatments for cancer.

```xml <problem> Current cancer treatments often lack specificity, leading to off-target effects and limited efficacy, particularly in solid tumors with complex microenvironments. Engineering effective tumor-infiltrating lymphocytes (TILs) to target and eradicate cancer cells remains a significant challenge. </problem> <solution> KSQ Therapeutics employs its CRISPRomics® platform to pinpoint and validate optimal therapeutic targets within the genome for cancer treatment. This platform facilitates the development of CRISPR/Cas9-engineered Tumor Infiltrating Lymphocytes (eTIL®) designed to selectively target and destroy tumor cells. By precisely editing TILs, KSQ aims to enhance their ability to infiltrate tumors, recognize cancer-specific antigens, and overcome immunosuppressive mechanisms within the tumor microenvironment. The eTIL® programs are designed to improve the efficacy and safety of adoptive cell therapies for solid tumors. </solution> <features> - CRISPRomics® platform for systematic, genome-scale target discovery and validation - CRISPR/Cas9-based engineering of TILs to enhance tumor-killing capabilities - eTIL® programs designed to improve tumor infiltration and persistence - Focus on developing treatments for solid tumors with unmet medical needs </features> <target_audience> The primary target audience includes patients with solid tumors who are refractory to standard treatments, as well as oncologists and researchers seeking innovative approaches to cancer immunotherapy. </target_audience> ```

What does KSQ Therapeutics do?

Where is KSQ Therapeutics located?

KSQ Therapeutics is based in Lexington, United States.

When was KSQ Therapeutics founded?

KSQ Therapeutics was founded in 2015.

How much funding has KSQ Therapeutics raised?

KSQ Therapeutics has raised 294000000.

Location

Lexington, United States

Founded

2015

Funding

294000000

Employees

84 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

KSQ Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

ksqtx.com 10K+

Crunchbase

Founded 2015 – Lexington, United States

Funding

Estimated Funding

$200M+

Team (75+)

No team information available.

Company Description

Problem

Current cancer treatments often lack specificity, leading to off-target effects and limited efficacy, particularly in solid tumors with complex microenvironments. Engineering effective tumor-infiltrating lymphocytes (TILs) to target and eradicate cancer cells remains a significant challenge.

Solution

KSQ Therapeutics employs its CRISPRomics® platform to pinpoint and validate optimal therapeutic targets within the genome for cancer treatment. This platform facilitates the development of CRISPR/Cas9-engineered Tumor Infiltrating Lymphocytes (eTIL®) designed to selectively target and destroy tumor cells. By precisely editing TILs, KSQ aims to enhance their ability to infiltrate tumors, recognize cancer-specific antigens, and overcome immunosuppressive mechanisms within the tumor microenvironment. The eTIL® programs are designed to improve the efficacy and safety of adoptive cell therapies for solid tumors.

Features

CRISPRomics® platform for systematic, genome-scale target discovery and validation

CRISPR/Cas9-based engineering of TILs to enhance tumor-killing capabilities

eTIL® programs designed to improve tumor infiltration and persistence

Focus on developing treatments for solid tumors with unmet medical needs

Target Audience

The primary target audience includes patients with solid tumors who are refractory to standard treatments, as well as oncologists and researchers seeking innovative approaches to cancer immunotherapy.